Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589944 | 0.83 | KDM4E (0.53) | KDM4ETSHRTDP1MAPTHSD17B10 | |
| SCHEMBL4737125 | 0.80 | KDM4E (0.56) | CYP4F2CYP4A11BAZ2BBAZ2ACASP1 | |
| SCHEMBL4737926 | 0.77 | CYP4F2 (0.55) | CYP4F2CYP4A11BAZ2BBAZ2ACASP1 | |
| SCHEMBL29076972 | 0.75 | TSHR (0.50) | KDM4ETSHRTDP1HSD17B10ALDH1A1 | |
| SCHEMBL3591506 | 0.75 | KDM4E (0.53) | KDM4ETSHRTDP1MAPTHSD17B10 | |
| SCHEMBL124872 | 0.74 | TSHR (0.43) | KDM4ETSHRHSD17B10CA1CA2 | |
| SCHEMBL236240 | 0.74 | CYP4F2 (0.57) | CYP4F2CYP4A11BAZ2BBAZ2AKDM4E | |
| SCHEMBL16433573 | 0.74 | KDM4E (0.48) | KDM4ETSHRMAPTALDH1A1MAPK1 | |
| SCHEMBL127223 | 0.73 | TSHR (0.45) | KDM4ETSHRHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL19601383 | 0.73 | KDM4E (0.54) | KDM4ETSHRTDP1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-2044050-A1 | NEW PYRIDINE ANALOGUES | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| US-20080039437-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039437-A1 | New Pyridine Analogues III | P2RY12, P2RY1, P2RY11 | CYP4F2 459/4885CYP4A11 157/4885BAZ2B 3057/4885 |
| US-20100069350-A1 | New Pyridine Analogues III | P2RY12, P2RY11, P2RY1 | CYP4F2 1343/4885CYP4A11 331/4885BAZ2B 2854/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | CYP4F2 166/4885CYP4A11 51/4885BAZ2B 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.